CD274 and neoplasm: Although PD-1/PD-L1 immunological checkpoint inhibitors have displayed unprecedented durable responses in tumor therapy, the objective response is still limited, such as for pembrolizumab (PD-1 mAb) in the treatment of melanoma, where the progression-free survival time for 47.3% of patients is only 6 months.